NCT06934941

Phase 1 Single Ascending Dose Study

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NM-101

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Neuramedy Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Phase 1, double-blind, placebo-controlled, single-centre, single ascending dose escalation study to assess safety and tolerability of a monoclonal antibody, NM-101 in healthy volunteer subject and multiple system atrophy (MSA) patients.

Detailed description

Phase 1, double-blind, placebo-controlled, single-centre, single ascending dose escalation study to assess safety and tolerability of a monoclonal antibody, NM-101 in healthy volunteer subject and multiple system atrophy (MSA) patients.

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	NM-101	NM-101 IV versus placebo
DRUG	Placebo	Placebo

Timeline

• Start date: 2024-11-25
• Primary completion: 2025-10-30
• Completion: 2026-03-30
• First posted: 2025-04-18
• Last updated: 2025-04-18

Locations

1 site across 1 country: South Korea